Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Perspective Therapeutics (CATX) Research & Development (2016 - 2025)

Historic Research & Development for Perspective Therapeutics (CATX) over the last 16 years, with Q3 2025 value amounting to $20.3 million.

  • Perspective Therapeutics' Research & Development rose 6909.71% to $20.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $64.2 million, marking a year-over-year increase of 7908.19%. This contributed to the annual value of $41.6 million for FY2024, which is 9538.27% up from last year.
  • Perspective Therapeutics' Research & Development amounted to $20.3 million in Q3 2025, which was up 6909.71% from $16.6 million recorded in Q2 2025.
  • Over the past 5 years, Perspective Therapeutics' Research & Development peaked at $20.3 million during Q3 2025, and registered a low of $362000.0 during Q1 2021.
  • In the last 5 years, Perspective Therapeutics' Research & Development had a median value of $5.5 million in 2023 and averaged $6.6 million.
  • Its Research & Development has fluctuated over the past 5 years, first tumbled by 1252.34% in 2022, then surged by 141282.05% in 2023.
  • Quarter analysis of 5 years shows Perspective Therapeutics' Research & Development stood at $535000.0 in 2021, then decreased by 12.52% to $468000.0 in 2022, then surged by 1412.82% to $7.1 million in 2023, then skyrocketed by 81.96% to $12.9 million in 2024, then soared by 57.87% to $20.3 million in 2025.
  • Its Research & Development stands at $20.3 million for Q3 2025, versus $16.6 million for Q2 2025 and $14.3 million for Q1 2025.